Search results for "From ACP Journal Club"
In persons aged ≥45 y, the mt-sRNA test had 94% sensitivity for colorectal cancer and 46% for advanced adenomas
The results of the industry-funded study support the use of the multitarget stool RNA (mt-sRNA) test for screening, but better adherence will be needed, and it is unclear whether the new test offers any advantages over current stool DNA testing, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2024/02/23/6.htm
23 Feb 2024
In symptomatic adults undergoing high-resolution manometry, long-term opioid use was linked to esophageal dysmotility
The results of a recent meta-analysis highlight the need for clinicians to widen their perspective on the risks of opioids to include both upper and lower GI motility disorders, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2023/12/22/8.htm
22 Dec 2023
In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo
An ACP Journal Club commentary said the high-quality randomized trial provides pragmatic guidance on amitriptyline dosing in patients with irritable bowel syndrome (IBS), as well as additional support for the drug as an option in primary care after first-line therapies fail.
https://gastroenterology.acponline.org/archives/2024/02/23/7.htm
23 Feb 2024
In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events
Given their overall safety and convenience, etrasimod and other oral sphingosine-1-phosphate receptor modulators can be considered as first-line therapy in clinically appropriate patients with ulcerative colitis (UC) who do not respond to 5-aminosalicylic acid medications, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2023/07/28/7.htm
28 Jul 2023
In older patients receiving aspirin, H pylori eradication reduced hospitalization or death due to peptic ulcer bleeding at 2.5 y
Several limitations of the trial may affect the extent to which the results will change current practice of Helicobacter pylori eradication in patients receiving aspirin, especially older patients, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2023/04/21/6.htm
21 Apr 2023
In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk
While the FDA has now approved risankizumab for adults with moderate to severe Crohn disease, understanding of the drug's role in relation to other biologic therapies is limited by broad exclusion criteria in randomized controlled trials, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2022/10/28/10.htm
28 Oct 2022
ACG-CAG provided suggestions for periendoscopic management of anticoagulants and antiplatelets
The recommendations from the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG), particularly those for withholding antithrombotics before planned endoscopic procedures, require individualized decision making with multidisciplinary input, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2022/07/22/7.htm
22 Jul 2022
In drug-refractory IBS, group CBT with interoceptive exposure improved symptoms and quality of life at 13 wk
Given the results of this small, randomized trial, a head-to-head comparison of multidisciplinary care versus group cognitive behavioral therapy (CBT) delivered over the internet for patients with irritable bowel syndrome (IBS) is now warranted, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2022/08/26/10.htm
26 Aug 2022
In persons with constipation or IBS-C, kiwifruit vs. psyllium increased spontaneous bowel movements
Findings of the randomized trial bolster recommendations of diet manipulation and lifestyle modifications for chronic constipation syndromes, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2023/05/26/7.htm
26 May 2023
In active UC, upadacitinib induced and maintained remission
JAK inhibitors, such as upadacitinib, represent an advance in the management of patients with ulcerative colitis (UC); however, it remains unclear whether the balance of efficacy versus risk favors one drug over the others, according to an ACP Journal Club commentary.
https://gastroenterology.acponline.org/archives/2022/10/28/11.htm
28 Oct 2022